Dr. Answer AI for Prostate Cancer: Predicting Biochemical Recurrence Following Radical Prostatectomy

Park, Jihwan; Rho, Mi Jung; Moon, Hyong Woo; Kim, Jae-Won; Lee, Chanjung; Kim, Dongbum; Kim, Choung‐Soo; Jeon, Seong Soo; Kang, Minyong; Lee, Ji Youl

doi:10.1177/15330338211024660

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Not only is it still in use, but many reviews and original scientific papers are still being published on its usability, safety, different formulation improvements, and targeted therapies. 86-108 Initially, DOX was confirmed to be effective for a few types of tumors only, although it is now used in many treatments to stop the growth of cancer cells in bones, 93,94 liver, 97,102 prostate, 99,101 cervical tissue, 100 breasts, 87,89,95,96,98,108 pancreas, 86,103 lung, 99,104 ovarium, 105 colon, 106,107 and the brain. 92…”

Section: Frl As Potential Organ Protector In Oncology Treatmentsmentioning

confidence: 99%

Potential Medical Use of Fullerenols After Two Decades of Oncology Research

Injac

2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Fullerenes are carbon molecules that are found in nature in various forms. They are composed of hexagonal and pentagonal rings that create closed structures. Almost 4 decades ago, fullerenes were identified in the form of C60 and C70, and following the award of the Nobel Prize in Chemistry for this discovery in 1996, many laboratories started working on their water-soluble derivatives that could be used in different industries, including pharmaceutical industries. One of the first fullerene forms that was the focus of different research groups was fullerenol, C60(OH) n ( n = 2-44). Both in-vitro and in-vivo studies have shown that polyhydroxylate fullerene derivatives can potentially be used as either antioxidative agents or cytostatics (depending on their co-administration, forms, and concentration/dose) in biological systems. The current review aimed to present a critical view of the potential applications and limitations of fullerenols in oncology, as understood from the past 2 decades of research.

show abstract

Section: Frl As Potential Organ Protector In Oncology Treatmentsmentioning

confidence: 99%

Potential Medical Use of Fullerenols After Two Decades of Oncology Research

Injac

2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…All patients underwent MRI on a 3 Tesla magnet (Trio Tim, Siemens Healthcare) with a pelvic antenna (9). The sequences of examination mainly included T2-weighted imaging, diffusion-weighted imaging, and dynamic contrastenhanced imaging.…”

Section: Mri Technique and Datamentioning

confidence: 99%

“…Multi-parametric MRI (mpMRI) of the prostate is used to optimize cancer detection [Prostate Imaging Reporting and Data System (PIRADS) 2.1 standardized criteria] (3,4), for therapeutic decision guidance and research of local recurrence after curative treatment (5,6). Several MRI prognostic factors are already related with cancer recurrence: PIRADS score (7), apparent diffusion coefficient (ADC) value (8)(9)(10), extra-prostatic extension, invasion of seminal vesicles, size of the lesion or apical location (before radiotherapy) (11). Dynamic acquisition also provides useful information for tumor detection and characterization (12).…”

Section: Introductionmentioning

confidence: 99%

Role of magnetic resonance imaging for preoperative prediction of early biochemical failure in localized prostate cancer

Cassin¹,

Walker²,

Blanc³

et al. 2023

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background: The purpose of our study was to assess preoperative clinical biological and Magnetic Resonance Imaging (MRI) predictive factors of early biochemical failure (BF), defined as persistence of significant post-operative plasmatic prostate specific antigen (PSA) level after radical prostatectomy (RP) in patients with localized prostate cancer (PCa).Methods: In a retrospective cohort study we included 142 patients from our university hospital with newly diagnosed PCa, who underwent 3T multiparametric MRI prior to RP. Only the MRI target lesions [Prostate Imaging Reporting and Data System (PIRADS) ≥3] with histological correspondence were considered significant. Clinical, biological, MRI and pathological preoperative data were studied.We performed univariate and multivariate logistic regression analysis to identify significant parameters associated with early BF.Results: Early BF occurred in 14% of patients (20/142). Patients with BF had higher PSA level at diagnosis, Gleason score, number of positive biopsies, size of the largest positive biopsy and higher National Comprehensive Cancer Network (NCCN) risk score (P<0.001 for all). According to MRI, they also had higher T stage and a higher size of capsular contact (P<0.001 for all). In contrast, there was no difference concerning neither ADC value, perfusion profile and zonal location of the index lesion. In multivariate analysis, the best combination of predictive factors of early BF was the association of preoperative Gleason score ≥4+3 {odds ratio (OR) =6.8 [1.4-32.5]; P=0.002} and T stage ≥3 on preoperative MRI {OR =17.4[3.2-94.9]; P<0.001} with an area under the curve (AUC) of 0.89 [99% confidence interval (CI): 0.77-1], a negative predictive value of 94% and a positive predictive value of 75%.Conclusions: Combination of simple preoperative biomarkers as Gleason score and T stage according to MRI accurately stratify the risk of early BF following RP. These results emphasize the pivotal role of preoperative MRI for the management of localized PCa.

show abstract